Topic Archives: Michael Shulman

Comments

  • SoGiAm

    #Biotech Best turnaround M&A $ARQL 20X $MRK BO in 2yr $ARRY $2s Multiple setbacks ➡️ 20X $PFE BO in 3yr $ECYT...

  • Avatar

    AGN has been a perpetual R&D disappointer. Botox SB ok, but the pipeline is mediocre at best, and stock is not that chea...

  • Avatar

    Travis ---you're right on-----The five he talks about are: ABBV, PFE, JNJ, MRK amd UNH...

  • Avatar

    ABBV has been in a down trend channel since 26 jan 2018...

  • Avatar

    Although this investment letter has done well in the past, since late 2018 it has been the fastest way to lose money I'v...

  • Avatar

    ABBV has been a very good stock over the past 1.5 years. One subscription service said to sell when it fell a month or t...

  • Jay Ram

    Must be Abbvie (ABBV). They want to tender $7.5B worth of their own stock. Sure makes me curious about buying, although ...

  • SoGiAm

    AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment Today 8:12 AM ET (MarketWatch) Sh...

  • SoGiAm

    $ENTA $ABBV MAVIRET™ (glecaprevir/pibrentasvir) Is Now Available in Japan for the Treatment of Chronic Hepatitis C Acr...

  • Avatar

    $AUPH. He made millions in Pharmacyclics (PCYC) which was sold to Abbvie (ABBV). Two or three years ago my first (very...

  • Avatar

    $ABBV $GILD $AMGN - An interesting article from IBD evaluating comparatively three biotech giants "AbbVie Stronger B...

  • Avatar

    $RGLS (long) http://tinyurl.com/z6qeum9 AbbVie ($ABBV) is touting impressive cure rates for its new daily hep C combo...

  • Avatar

    GILD's HEP C scripts latest data. Gilead Sciences: Does Anyone Care About Hep-C Anymore? By Ben Leviso...

  • Avatar

    Got this teaser for a prescription buy to Money Map Press.It was easy to figure out the company.It is Orasure Technologi...

  • Avatar

    I started watching Mike Ward's pitch this afternoon and decided I could dope this out on my own. I spent 6 hours learnin...

  • Avatar

    The following is an excerpt from a piece on GILD: "A group of developers are racing ahead in the clinic with new hep C ...

  • karmaswimswami

    Readers here who might be more comfortable with a blue-chip rather than a speculative pick might really want to take a l...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info